Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Manufacturing Issues Should Be Focus Of User Fee Program, Firms Say

Executive Summary

Manufacturing issues will need the most attention in biosimilar applications and FDA should structure its user fee and review system to reflect it, several potential biosimilar sponsors said.

You may also be interested in...



Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say

Brand and generic drug trade associations disagree with FDA’s proposal to have biosimilar sponsors pay a product development fee before even submitting a marketing application.

Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say

Brand and generic drug trade associations disagree with FDA’s proposal to have biosimilar sponsors pay a product development fee before even submitting a marketing application.

Biosimilar User Fees Would Be Same As BLAs, Only Earlier

FDA's proposed biosimilar product development fee would be charged upon IND submission, but subtracted from marketing application fee.

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel